Skin invasion and prognosis in node negative breast cancer: a retrospective study

被引:4
作者
Tada, Keiichiro [1 ]
Morizono, Hidetomo [1 ]
Iijima, Kotaro [1 ]
Miyagi, Yumi [1 ]
Nishimura, Seiichiro [1 ]
Makita, Masujiro [1 ]
Horii, Rie [2 ]
Akiyama, Futoshi [2 ]
Iwase, Takuji [1 ]
机构
[1] Canc Inst Hosp, Dept Breast Surg, Tokyo, Japan
[2] Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo 170, Japan
关键词
D O I
10.1186/1477-7819-6-10
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The impact of skin invasion in node negative breast cancer is uncertain. Methods: We determined the prognosis in 97 node negative breast cancer patients ( case group) who had tumors with skin invasion. Then we compared these patients with 4500 node negative invasive breast cancer patients treated surgically in the same period. Results: Patients with skin invasion tended to be older, had more invasive lobular carcinoma and larger tumor size, and were less likely to have breast conserving surgery than those in the control group. The 5-year disease-free survival rate in the case group was 94.0%. There was no significant difference in the 10-year disease-specific overall survival rates in terms of skin invasion in node negative patients (90.7% in the case group, 92.9% in the control group; p = 0.2032). Conclusion: Results suggest that skin invasion has no impact on survival in node negative invasive breast cancer patients. The adjuvant regimens which the individual institute applies for node negative breast cancer should be used regardless of skin invasion.
引用
收藏
页数:5
相关论文
共 18 条
[1]   Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance [J].
Arpino, G ;
Weiss, H ;
Lee, AV ;
Schiff, R ;
De Placido, S ;
Osborne, CK ;
Elledge, RM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1254-1261
[2]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[3]  
2-H
[4]   Concordance among gene-expression-based predictors for breast cancer [J].
Fan, Cheng ;
Oh, Daniel S. ;
Wessels, Lodewyk ;
Weigelt, Britta ;
Nuyten, Dimitry S. A. ;
Nobel, Andrew B. ;
van't Veer, Laura J. ;
Perou, Charles M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (06) :560-569
[5]  
FISHER ER, 1993, CANCER-AM CANCER SOC, V71, P2141, DOI 10.1002/1097-0142(19930315)71:6+<2141::AID-CNCR2820711603>3.0.CO
[6]  
2-F
[7]   Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 [J].
Goldhirsch, A ;
Glick, JH ;
Gelber, RD ;
Coates, AS ;
Thürlimann, B ;
Senn, H ;
Albain, KS ;
Bergh, J ;
Castiglione-Gertsch, M ;
Coates, AS ;
Costa, A ;
Cuzick, J ;
Davidson, N ;
Forbes, JF ;
Gelber, RD ;
Goss, P ;
Harris, J ;
Glick, JH ;
Goldhirsch, A ;
Howell, A ;
Ingle, JN ;
Jakesz, R ;
Jassem, J ;
Kaufmann, M ;
Martin, M ;
Mauriac, L ;
Morrow, M ;
Mouridsen, HT ;
Namer, M ;
Piccart-Gebhart, MJ ;
Possinger, K ;
Pritchard, K ;
Rutgers, EJT ;
Thürlimann, B ;
Viale, G ;
Wallgren, A ;
Wood, WC .
ANNALS OF ONCOLOGY, 2005, 16 (10) :1569-1583
[8]   Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined [J].
Iyer, RV ;
Hanlon, A ;
Fowble, B ;
Freedman, G ;
Nicolaou, N ;
Anderson, P ;
Hoffman, J ;
Sigurdson, E ;
Boraas, M ;
Torosian, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (05) :1177-1183
[9]   Cyclin E and survival in patients with breast cancer. [J].
Keyomarsi, K ;
Tucker, SL ;
Buchholz, TA ;
Callister, M ;
Ding, Y ;
Hortobagyi, GN ;
Bedrosian, I ;
Knickerbocker, C ;
Toyofuku, W ;
Lowe, M ;
Herliczek, TW ;
Bacus, SS .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (20) :1566-1575
[10]   Predictive impact of urokinase-type plasminogen activator: Plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer [J].
Manders, P ;
Tjan-Heijnen, VCG ;
Span, PN ;
Grebenchtchikov, N ;
Foekens, JA ;
Beex, LVAM ;
Sweep, CGJ .
CANCER RESEARCH, 2004, 64 (02) :659-664